Related Experiment Video
Updated: Mar 17, 2026
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
12.7K
Natalizumab: a new therapy for acute ischemic stroke?
Alba Simats1, Teresa García-Berrocoso1, Joan Montaner1,2
1a Neurovascular Research Laboratory, Institut de Recerca, Hospital Universitari Vall d'Hebron (VHIR) , Universitat Autónoma de Barcelona , Barcelona , Spain.
Expert Review of Neurotherapeutics
|August 2, 2016
Summary
Natalizumab, an anti-CD49d antibody, shows promise for ischemic stroke by reducing neuroinflammation. Further clinical trials are needed to confirm its neuroprotective role and functional benefits in stroke patients.
Area of Science:
- Neuroscience
- Immunology
- Neurology
Background:
- Natalizumab is a humanized antibody targeting alpha-4 integrin (CD49d), known for treating multiple sclerosis by limiting leukocyte migration.
- Experimental studies on anti-CD49d antibody efficacy in ischemic stroke have yielded conflicting results, raising questions about its therapeutic potential.
Purpose of the Study:
- To review experimental studies on CD49d blockage for ischemic stroke and identify reasons for inconsistent outcomes.
- To discuss preliminary results from the ACTION phase II clinical trial evaluating natalizumab in stroke patients.
- To provide an overview of neuroinflammation mitigation as a neuroprotective strategy post-stroke.
Main Methods:
- Literature review of experimental studies on CD49d blockage in ischemic stroke.
- Analysis of potential causes for discrepancies in experimental study results.
- Discussion of preliminary data from the ACTION clinical trial (Phase II) for natalizumab in stroke.
Main Results:
- Experimental studies on CD49d blockage for ischemic stroke show divergent results.
- Preliminary results from the ACTION trial suggest natalizumab may have positive effects on functional outcomes in stroke patients.
- The mechanism by which natalizumab improves functional outcomes without reducing infarct volume requires further investigation.
Conclusions:
- Despite inconclusive experimental data, natalizumab shows potential for improving functional outcomes in ischemic stroke.
- Further research and clinical trials are necessary to confirm the neuroprotective role of natalizumab in ischemic stroke.
- Mitigating post-stroke neuroinflammation is an emerging and important neuroprotective strategy.
Keywords:
NatalizumabStrokealpha-4 integrininflammationleukocyte infiltrationneutrophils and T-lymphocytesMore Related Videos
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
900
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
900
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
585
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
585
01:28Acute Coronary Syndrome IV: Interprofessional Care
391
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
391
01:17Ischemic Heart Disease: Overview
3.8K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K